Tianjin Chase Sun Pharmaceutical Co Ltd Cash Flow Reinvestment Rate
Tianjin Chase Sun Pharmaceutical Co Ltd cash flow reinvestment rate. Tianjin Chase Sun Pharmaceutical Co Ltd (300026) has a Cash Flow Reinvestment Rate of 0.14x as of September 2025, reinvesting CN¥21.58 Million (capex CN¥21.58 Million ) from operating cash flow of CN¥153.30 Million. Explore Tianjin Chase Sun Pharmaceutical Co Ltd (300026) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2024)
Cash flow reinvestment rate of Tianjin Chase Sun Pharmaceutical Co Ltd from 2006 to 2024. Historical reinvestment intensity for Tianjin Chase Sun Pharmaceutical Co Ltd across 19 annual periods. Explore Tianjin Chase Sun Pharmaceutical Co Ltd (300026) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Tianjin Chase Sun Pharmaceutical Co Ltd Cash Flow Reinvestment Rate by Year (2006–2024)
Tianjin Chase Sun Pharmaceutical Co Ltd cash flow reinvestment rate by year from 2006 to 2024. Year-by-year capital reinvestment analysis for Tianjin Chase Sun Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see cash flow conversion of Tianjin Chase Sun Pharmaceutical Co Ltd.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.23x | CN¥199.91 Million | CN¥852.24 Million | CN¥193.12 Million | ▼ -52.1% |
| 2023 | 0.49x | CN¥750.04 Million | CN¥1.53 Billion | CN¥347.12 Million | ▼ -75.6% |
| 2022 | 2.01x | CN¥1.50 Billion | CN¥745.35 Million | CN¥770.27 Million | ▲ +13.8% |
| 2021 | 1.77x | CN¥692.19 Million | CN¥391.60 Million | CN¥677.45 Million | ▼ -38.7% |
| 2020 | 2.88x | CN¥566.93 Million | CN¥196.66 Million | CN¥563.78 Million | ▼ -5.9% |
| 2019 | 3.06x | CN¥662.25 Million | CN¥216.10 Million | CN¥591.01 Million | ▲ +302.4% |
| 2018 | 0.76x | CN¥295.61 Million | CN¥388.19 Million | CN¥294.89 Million | ▲ +13.6% |
| 2017 | 0.67x | CN¥497.73 Million | CN¥742.38 Million | CN¥383.34 Million | ▼ -70.6% |
| 2016 | 2.28x | CN¥1.02 Billion | CN¥448.08 Million | CN¥415.52 Million | ▲ +1.9% |
| 2015 | 2.24x | CN¥270.51 Million | CN¥121.00 Million | CN¥223.35 Million | ▲ +87.9% |
| 2014 | 1.19x | CN¥178.37 Million | CN¥149.94 Million | CN¥178.37 Million | ▲ +59.4% |
| 2013 | 0.75x | CN¥107.20 Million | CN¥143.60 Million | CN¥107.20 Million | ▼ -48.6% |
| 2012 | 1.45x | CN¥221.17 Million | CN¥152.21 Million | CN¥221.17 Million | ▼ -80.3% |
| 2011 | 7.37x | CN¥262.51 Million | CN¥35.64 Million | CN¥262.51 Million | ▲ +201.7% |
| 2010 | 2.44x | CN¥112.90 Million | CN¥46.25 Million | CN¥112.90 Million | ▲ +561.8% |
| 2009 | 0.37x | CN¥49.82 Million | CN¥135.06 Million | CN¥49.82 Million | ▼ -40.6% |
| 2008 | 0.62x | CN¥48.28 Million | CN¥77.74 Million | CN¥48.28 Million | ▲ +661.3% |
| 2007 | 0.08x | CN¥5.87 Million | CN¥72.01 Million | CN¥5.87 Million | ▼ -96.8% |
| 2006 | 2.54x | CN¥3.12 Million | CN¥1.22 Million | CN¥3.12 Million | — |